Churchill Downs (NASDAQ:CHDN – Get Free Report) had its price target cut by analysts at Wells Fargo & Company from $132.00 to $120.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 43.28% from the […]

ZoomInfo Technologies (NASDAQ:GTM – Get Free Report) had its price target dropped by stock analysts at Citigroup from $4.00 to $2.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “sell” rating on the stock. Citigroup’s target price points to a potential downside of 31.86% from the […]

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price cut by equities research analysts at Piper Sandler from $855.00 to $854.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price target points to a potential […]

Wynn Resorts (NASDAQ:WYNN – Get Free Report) had its price objective reduced by stock analysts at Barclays from $139.00 to $134.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the casino operator’s stock. Barclays‘s target price would suggest a potential upside of 36.56% from the […]

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective dropped by stock analysts at Morgan Stanley from $168.00 to $166.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price points to a potential upside of 22.49% from the company’s […]

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target lowered by Cantor Fitzgerald from $785.00 to $750.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 14.63% from the stock’s previous close. […]